Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
FORT WAYNE, Ind., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Vera Bradley (NASDAQ: VRA) (the "Company”) today announced the appointment of Andrew Meslow, former CEO of L Brands and Bath and Body Works, to the ...
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...
The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback